Similarly, dual-target TsAbs engaging CD3/CD28 and a tumor-associated antigen (TAA) are being developed to amplify immune responses in MM by co-engaging T-cell activation and tumor specificity in a single construct [78]. The gene discussed is CD28; the disease is neoplasm.